AQEMIA

TECH-POWERED DRUG DISCOVERY, ROOTED IN FUNDAMENTAL PHYSICS AND GENERATIVE AI

AQEMIA originates from deep-physics research and combines proprietary, physics-based algorithms with next-generation generative AI.

The platform enables preclinical drug discovery across oncology, immunology, neurology, and cardiology, with a focus on designing truly novel drug candidates over me-too compounds.

KEY FIGURES & MILESTONES

2019
Founded as a deeptech spin-off from fundamental research in statistical and quantum mechanics

12+ years
Research at CNRS, École Normale Supérieure, Oxford and Cambridge

2 Offices
Paris (FR) & London (UK)

40+ scientific articles
On AQEMIA's proprietary method

70+ employees
A multidisciplinary team blending science, tech & pharma expertise

$100M Funding
$70M in 2024 – Cathay Innovation, Wendel, Bpifrance, Eurazeo, Elaia

PIPELINE & COLLABORATION

50+ active programs
Most advanced programs showing efficacy in cancer animal models

Strategic Partnerships
With Servier, J&J & Sanofi — including a $150M multi- year deal with Sanofi in 2024

FOUNDERS

Maximilien Levesque, PhD
CEO

Emmanuelle Martiano-Rolland
COO